These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Fulkerson CM; Knapp DW Vet J; 2015 Aug; 205(2):217-25. PubMed ID: 25747698 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. Yokota S; Yonezawa T; Momoi Y; Maeda S J Vet Med Sci; 2022 May; 84(5):666-674. PubMed ID: 35387955 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target. Millanta F; Impellizeri J; McSherry L; Rocchigiani G; Aurisicchio L; Lubas G Vet Comp Oncol; 2018 Jun; 16(2):297-300. PubMed ID: 28871659 [TBL] [Abstract][Full Text] [Related]
11. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. Dhawan D; Hahn NM; Ramos-Vara JA; Knapp DW PLoS Genet; 2018 Aug; 14(8):e1007571. PubMed ID: 30089113 [TBL] [Abstract][Full Text] [Related]
12. Expression of cell cycle regulators, 14-3-3σ and p53 proteins, and vimentin in canine transitional cell carcinoma of the urinary bladder. Suárez-Bonnet A; Herráez P; Aguirre M; Suárez-Bonnet E; Andrada M; Rodríguez F; Espinosa de Los Monteros A Urol Oncol; 2015 Jul; 33(7):332.e1-7. PubMed ID: 25979650 [TBL] [Abstract][Full Text] [Related]
13. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019). Gedon J; Kehl A; Aupperle-Lellbach H; von Bomhard W; Schmidt JM Vet Comp Oncol; 2022 Jun; 20(2):449-457. PubMed ID: 34878687 [TBL] [Abstract][Full Text] [Related]
14. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors. Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713 [TBL] [Abstract][Full Text] [Related]
16. Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. Rankin WV; Henry CJ; Turnquist SE; Turk JR; Beissenherz ME; Tyler JW; Rucker EB; Knapp DW; Rodriguez CO; Green JA Vet Comp Oncol; 2008 Sep; 6(3):141-50. PubMed ID: 19178674 [TBL] [Abstract][Full Text] [Related]
17. Flow cytometric DNA ploidy analysis in canine transitional cell carcinoma of urinary bladders. Clemo FA; DeNicola DB; Carlton WW; Morrison WB; Walker E Vet Pathol; 1994 Mar; 31(2):207-15. PubMed ID: 8203084 [TBL] [Abstract][Full Text] [Related]
18. Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma. Finotello R; Schiavo L; Ressel L; Frohmader A; Silvestrini P; Verin R J Comp Pathol; 2019 Jul; 170():1-9. PubMed ID: 31375151 [TBL] [Abstract][Full Text] [Related]
19. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061 [TBL] [Abstract][Full Text] [Related]
20. A review of the current standing of microRNA expression in canine urothelial carcinoma. Varvil MS; Dos Santos AP Am J Vet Res; 2024 Oct; 85(10):. PubMed ID: 39047791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]